{"url_path":"/sec/cldi/8-k/2026-06-23/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1855485/0001493152-26-029710-index.html","accession_number":"0001493152-26-029710","cik":"0001855485","ticker":"CLDI","issuer_name":"Calidi Biotherapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1855485/0001493152-26-029710-index.html","primary_entity_key":"0001855485","primary_entity_name":"Calidi Biotherapeutics, Inc."},"word_count":125,"has_tables":true,"body_markdown":"**Item\n8.01 Other Events.**\n\n \n\nOn\nJune 23, 2026, the Board at the recommendation of the Nominating and Corporate Governance Committee, and as permitted by the Bylaws of\nthe Company, increased the size of the Board from five (5) to six (6) members, by increasing the number of Class III directors on the\nBoard. The information under Item 5.02 above, as it relates to the appointment of a Class III director is also incorporated herein by\nreference. Additionally, in connection with Dr. Sanders’ appointment to the Board’s Audit Committee, the Board removed Scott\nLeftwich as a member of the Audit Committee, effective as of June 17, 2026. Mr. Leftwich’s removal from the Audit Committee does\nnot affect his continued service as a member of the Board."}